Introduction: When acute myeloid leukemia first manifests, during treatment, or after relapsing, immature myeloid cells make up the extramedullary tumor known as oral myeloid sarcoma (AML). This article's goals are to evaluate instances that have been reported in the literature and to present the clinical characteristics of oral myeloid sarcoma.
Case presentation: This case involves a 45-year-old male patient who reported considerable pain and spontaneous bleeding in the vestibular gingiva on the left side, next to the upper premolars. The clinical findings of AML included petechiae in the area of the patient's lower limbs due to thrombocytopenia, which was confirmed in the CBC, in addition to the patient's presenting symptoms of fever, weakness, bodily aches, and diarrhea. A week before to his hospital admission, he started experiencing these symptoms. The initial lab findings showed that there were 231,410 total leukocytes/mm3, 27,000 platelets/mm3, 3.39 million mm/mm3 of red blood cells, and 222,154 circulating blasts, or 96% of total leukocytes. Myelography performed shortly after admission to the hospital showed the presence of cancerous cells, and immunohistochemistry confirmed the diagnosis of AML. Even though PAX-5, CD20, TDT, and CD3 were all negative, myeloperoxidase was positive.
Conclusion: We draw the conclusion that oral myeloid sarcoma is uncommon and that it is challenging for both doctors and dentists to diagnose and treat.
Atherosclerotic plaque buildup in the epicardial arteries is a hallmark of chronic coronary heart failure (CHF). Due to the morbidity, mortality, and economical significance of this condition, it is imperative that people with CHF have an accurate diagnosis as soon as possible and receive cost-effective treatment. In order to handle these patients for dental treatment, the dentist’s and cardiologist’s expertise must be current and they must look for the safest way to approach the patients. The purpose of this article is to provide dentists and cardiologists with information on the best practices for treating patients with CHF who also have dental problems. Methodology: The electronic databases PubMed/Medline®, LILACS®, and Scopus® were searched for an integrated review using the terms “Dental Care for Chronically III AND Coronary disease AND Myocardial Ischemia.” We considered articles in Portuguese, English, and Spanish that were fully accessible online between 2000 and 2022 addressing the main consequences of chronic coronary failure and dental care. Results: Ninety-three articles were found in the databases. After screening, seven of them met all the prerequisites and were included in the review. Conclusion: It is critical to provide information to guide dentists and cardiologists in the care of individuals with CHF in order to provide safety in clinical and surgical dental care.
A doença falciforme é uma hemoglobinopatia autossômica hereditária, na qual ocorre uma mutação na cadeia beta da hemoglobina. Essa mutação leva a uma alteração da hemoglobina normal HbA, em hemoglobina C (HbC) ou hemoglobina D (HbD), o que implica em um quadro de desoxigenação tecidual e falcização das hemácias, que determina sua destruição prematura e anemia hemolítica. As características clínicas da doença variam em episódios de dor, decorrente do mecanismo de vaso oclusão, danos a órgãos e infecções, principalmente oportunistas, devido ao quadro grave de imunossupressão desses pacientes. As complicações odontológicas são de grande relevância, levando em consideração que esses pacientes podem apresentar diversas manifestações bucais e uma infecção dentária complicada por uma crise falciforme, aumenta significativamente, a probabilidade de admissão hospitalar.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.